top of page

DCSCA Compliance Raises Concerns for 340B Covered Entities and Pharmacies

The Drug Supply Chain Security Act (DCSCA), a critical piece of legislation aimed at securing the pharmaceutical supply chain, has introduced a new layer of compliance challenges for healthcare providers participating in the 340B Drug Pricing Program. As the DCSCA's requirements continue to roll out, covered entities and pharmacies are increasingly concerned about the potential impact on their operations, financial stability, and ability to serve vulnerable populations.

 

Understanding the DCSCA

The DCSCA, enacted in 2013 as part of the Drug Quality and Security Act (DQSA), is designed to enhance the security of the pharmaceutical distribution supply chain in the United States. The law mandates the establishment of an electronic, interoperable system to trace prescription drugs as they move through the supply chain. This system aims to prevent counterfeit, stolen, contaminated, or otherwise harmful drugs from reaching patients.

 

By 2023, the DCSCA requires full implementation of a system that will allow for the tracing of drugs from the manufacturer to the pharmacy or healthcare provider. This includes stringent requirements for documentation, product verification, and reporting of suspicious activities.

 

340B Program Overview

The 340B Drug Pricing Program allows eligible healthcare providers, known as covered entities, to purchase outpatient drugs at significantly reduced prices. The savings generated from these discounts are intended to support the care of underserved and low-income patients. The program has become a lifeline for many safety-net hospitals, clinics, and pharmacies.

 

DCSCA Compliance Challenges for 340B Entities

As DCSCA compliance becomes mandatory, 340B covered entities and their contract pharmacies face several significant challenges:


Increased Administrative Burden: The DCSCA's stringent tracking and documentation requirements add to the already complex administrative responsibilities that 340B entities must manage. The need to maintain detailed transaction records and ensure compliance with both DCSCA and 340B regulations can strain resources, particularly for smaller organizations.

 

Cost Implications: Implementing the necessary technology and processes to comply with DCSCA can be costly. Many 340B entities operate with thin margins and may struggle to absorb these additional expenses without compromising patient care or other critical services.

 

Supply Chain Disruptions: DCSCA compliance could lead to disruptions in the supply chain, particularly for drugs purchased through the 340B program. Any delays or issues in verifying the authenticity and tracing of drugs could impact the timely delivery of medications to patients who depend on them.

 

Contract Pharmacy Relationships: The DCSCA's requirements may also complicate the relationships between 340B covered entities and their contract pharmacies. Ensuring that both parties are compliant with DCSCA regulations requires effective coordination and communication, which can be challenging in an already complex environment.

 

Risk of Non-Compliance: Non-compliance with DCSCA can lead to severe consequences, including fines, penalties, and potential exclusion from the 340B program. This risk adds to the existing pressure on covered entities to maintain compliance with 340B regulations, which are subject to increasing scrutiny.

 


Provider and Pharmacy Concerns

Healthcare providers and pharmacies involved in the 340B program have expressed concerns about the impact of DCSCA compliance on their operations. Many fear that the additional administrative and financial burdens could reduce their ability to provide care to underserved populations. The potential for supply chain disruptions also raises alarm, as it could lead to drug shortages or delays in treatment.

 

Additionally, there is concern that DCSCA compliance may disproportionately affect smaller, rural providers who may lack the resources to implement the necessary systems and processes. These providers are often the most reliant on the 340B program to sustain their operations and serve vulnerable communities.

 

Regulatory Guidance and Support

Regulatory agencies, including the Food and Drug Administration (FDA), have provided guidance to help entities comply with DCSCA requirements. However, many covered entities and pharmacies feel that more support is needed, particularly in the form of financial assistance or resources to help with the transition.

 

Industry associations and advocacy groups are also working to raise awareness of the challenges faced by 340B entities and to advocate for solutions that mitigate the   impact of DCSCA compliance on these critical healthcare providers.

 

The DCSCA's requirements present significant challenges for 340B covered entities and pharmacies, adding to the already complex regulatory landscape they must navigate. As they work to comply with these new mandates, there is growing concern about the potential impact on their ability to serve vulnerable populations. Continued dialogue between regulators, industry stakeholders, and advocacy groups will be essential to ensure that the goals of the DCSCA are met without compromising the mission of the 340B program.

 

 

Recent Posts

See All

Office: 208.258.8139

Copyright 2023 ACI 340B Management

  • Facebook
  • Twitter
  • LinkedIn
bottom of page